Disease-modifying drugs in relapsing-remitting multiple sclerosis: evidence-based treatment algorithm for Latin America

被引：0
|
作者：
Finkelsztejn, A.
Gabbai, A. A.
Fragoso, Y. D.
Carra, A.
Macias-Islas, M. A.
Arcega Revilla, R.
Garcia Bonitto, J.
Oehninger Gatti, C. L.
Orozco Escobar, G.
Tarulla, A.
Vergara, F.
Vizcarra, D.
机构：
[1] Hosp Clin, Porto Alegre, RS, Brazil
[2] Univ Fed Sao Paulo, Sao Paulo, Brazil
[3] Univ Metropolitana Santos, Santos, Brazil
[4] Hosp Britan, Buenos Aires, DF, Argentina
[5] Univ Guadalajara, CUCS, Guadalajara 44430, Jalisco, Mexico
[6] Inst Mexicano Seguro Social, Hosp Especialidades, Puebla, Mexico
[7] Colombian Multiple Sclerosis Res & Treatment Comm, Bogota, Colombia
[8] Hosp Clin Montevideo, Montevideo, Uruguay
[9] Hosp Patrocinio Penuela Ruiz, San Cristobal, Venezuela
[10] Inst Invest Med Alfredo Lanari, Buenos Aires, DF, Argentina
[11] Univ Los Andes, Santiago, Chile
[12] Univ Peruana Cayetano Heredia, Lima, Peru
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P997
引用
收藏
页码：S452 / S453
页数：2
相关论文
共 50 条
  • [1] Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents
    Finkelsztejn, Alessandro
    Gabbai, Alberto Alain
    Fragoso, Yara Dadalti
    Carra, Adriana
    Angel Macias-Islas, Miguel
    Arcega-Revilla, Raul
    Garcia-Bonitto, Juan
    Luis Oehninger-Gatti, Carlos
    Orozco-Escobar, Geraldine
    Tarulla, Adriana
    Vergara, Fernando
    Vizcarra, Darwin
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2012, 70 (10) : 799 - 806
  • [2] Treatment with disease-modifying drugs does not alter disability in relapsing-remitting multiple sclerosis
    Rolak, Loren A.
    Bejaoui, Khemissa
    Matti, Charmaine
    Foss, Dawn
    MULTIPLE SCLEROSIS, 2008, 14 : S176 - S176
  • [3] Disease-modifying therapies in relapsing-remitting multiple sclerosis
    Gonzalez-Andrade, Fabricio
    Luis Alcaraz-Alvarez, Jose
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 365 - 373
  • [4] Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics
    Rudick, RA
    ARCHIVES OF NEUROLOGY, 1999, 56 (09) : 1079 - 1084
  • [5] Oral disease-modifying therapies for relapsing-remitting multiple sclerosis
    Thomas, Rachel Hutchins
    Wakefield, Richard A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (01) : 25 - 38
  • [6] Disease-modifying therapy in adult relapsing-remitting multiple sclerosis
    Rosenzweig, Tamara M.
    Hartman, Sarah
    MacKenzie, Elizabeth
    FORMULARY, 2010, 45 (08) : 252 - 262
  • [7] Established disease-modifying treatments in relapsing-remitting multiple sclerosis
    Oh, Jiwon
    O'Connor, Paul W.
    CURRENT OPINION IN NEUROLOGY, 2015, 28 (03) : 220 - 229
  • [8] Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis
    Calabrese, M.
    Bernardi, V.
    Atzori, M.
    Mattisi, I.
    Favaretto, A.
    Rinaldi, F.
    Perini, P.
    Gallo, P.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (04) : 418 - 424
  • [9] Discontinuation of Disease-Modifying Therapy for Patient with Relapsing-Remitting Multiple Sclerosis
    Yano, Hajime
    Gonzalez, Cindy T.
    Healy, Brian C.
    Glanz, Bonnie I.
    Weiner, Howard L.
    Chitnis, Tanuja
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 47 - 47
  • [10] Disease-modifying therapy in relapsing-remitting multiple sclerosis: efficacy is paramount
    Cristiano, E
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, : 3 - 7
12345